{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:01:19Z","timestamp":1787169679969,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Women with polycystic ovarian syndrome (PCOS) often have anovulatory infertility requiring ovulation induction with letrozole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study aimed to determine the prevalence and phenotypic categorisation of infertile PCOS women and to assess ovulatory response and pregnancy rates of PCOS phenotypes with sequential letrozole dose escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Setting and Design:<\/jats:title>\n                    <jats:p>This was a prospective observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>One hundred seventy-five infertile PCOS women were enrolled. One hundred fifty-six women received ovulation induction as per the protocol with sequential letrozole dose escalation in each subsequent cycle (2.5 mg, 5 mg and 7.5 mg). Responses were assessed by ovulation and\/or pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>Descriptive statistics were elaborated by means, medians, frequencies and percentages. Group comparisons and linear correlation between two continuous variables were done using appropriate statistical tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eighty-seven (49.7%) women were Phenotype A; 11 (6.3%) were Phenotype B; 20 (11.4%) were Phenotype C and 57 (32.6%) were Phenotype D in our study. After excluding the lost to follow up participants in each induction cycle, 33.3% (2.5 mg dose); 62.8% (5 mg dose) and 78.9% (7.5 mg dose) women responded to letrozole. A significant increase in ovulation to escalating letrozole doses was noted (Phenotype A: 35.1% to 2.5 mg, 53.7% to 5 mg and 72.7% to 7.5 mg; Phenotype B: 30% to 2.5 mg and 80% to 5 mg; Phenotype C: 35.3% to 2.5 mg and 87.5% to 5 mg and Phenotype D: 30.8% to 2.5 mg, 65.6% to 5 mg and 87.5% to 7.5 mg). Fifty-six of 156 (35.9%) infertile PCOS women achieved pregnancy; increase in pregnancy rates with escalated doses of letrozole was noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>All PCOS phenotypes show a similar response to escalating doses of letrozole. The role of phenotypic sub-categorisation for variable response to letrozole as an ovulation-inducing agent is uncertain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jhrs.jhrs_141_21","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T13:29:23Z","timestamp":1648646963000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Prevalence of Polycystic Ovarian Syndrome, Phenotypes and their Ovulation Response to Sequential Letrozole Dose Escalation among Infertile Women at a Tertiary Care Centre in Southern India"],"prefix":"10.4103","volume":"15","author":[{"given":"Abha","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Swamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujoy","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangisapu","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nagaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20240905","first-page":"2185","article-title":"Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations","volume":"123","author":"Ma","year":"2010","journal-title":"Chin Med J (Engl"},{"key":"R3-7-20240905","first-page":"CD010287","article-title":"Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome","volume":"5","author":"Franik","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-7-20240905","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","article-title":"Clinical assessment of body hair growth in women","volume":"21","author":"Ferriman","year":"1961","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-7-20240905","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5694\/mja11.10553","article-title":"Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia","volume":"196","author":"Boyle","year":"2012","journal-title":"Med J Aust"},{"key":"R8-7-20240905","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"R9-7-20240905","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1477-7827-10-96","article-title":"Polycystic ovary syndrome in Salvador, Brazil: A prevalence study in primary healthcare","volume":"10","author":"Gabrielli","year":"2012","journal-title":"Reprod Biol Endocrinol"},{"key":"R10-7-20240905","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/humrep\/det262","article-title":"Prevalence of polycystic ovary syndrome in women in China: A large community-based study","volume":"28","author":"Li","year":"2013","journal-title":"Hum Reprod"},{"key":"R11-7-20240905","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000358485","article-title":"Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China","volume":"77","author":"Zhuang","year":"2014","journal-title":"Gynecol Obstet Invest"},{"key":"R12-7-20240905","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/humrep\/det469","article-title":"The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone","volume":"29","author":"Lauritsen","year":"2014","journal-title":"Hum Reprod"},{"key":"R13-7-20240905","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/aje\/kwn137","article-title":"A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka","volume":"168","author":"Kumarapeli","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R14-7-20240905","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1477-7827-9-39","article-title":"The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study","volume":"9","author":"Tehrani","year":"2011","journal-title":"Reprod Biol Endocrinol"},{"key":"R15-7-20240905","first-page":"238","article-title":"The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria","volume":"62","author":"Mehrabian","year":"2011","journal-title":"Endokrynol Pol"},{"key":"R16-7-20240905","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria","volume":"27","author":"Yildiz","year":"2012","journal-title":"Hum Reprod"},{"key":"R17-7-20240905","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejogrb.2013.12.018","article-title":"To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran","volume":"174","author":"Rashidi","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R18-7-20240905","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-7-20240905","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2605.2005.00623.x","article-title":"Development of polycystic ovary syndrome: Involvement of genetic and environmental factors","volume":"29","author":"Franks","year":"2006","journal-title":"Int J Androl"},{"key":"R20-7-20240905","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.0.1380269","article-title":"Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome","volume":"138","author":"Diamanti-Kandarakis","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"R21-7-20240905","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1210\/jc.2006-1327","article-title":"Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: The impact of weight on phenotype and metabolic features","volume":"91","author":"Welt","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-7-20240905","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/humupd\/dmp008","article-title":"Metabolic features of the reproductive phenotypes of polycystic ovary syndrome","volume":"15","author":"Moran","year":"2009","journal-title":"Hum Reprod Update"},{"key":"R23-7-20240905","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/ijem.IJEM_30_19","article-title":"Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene","volume":"23","author":"Sachdeva","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"key":"R24-7-20240905","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1471-0528.2009.02347.x","article-title":"Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population","volume":"116","author":"Zhang","year":"2009","journal-title":"BJOG"},{"key":"R25-7-20240905","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000277640","article-title":"Prevalence of polycystic ovary syndrome and related disorders in mexican women","volume":"69","author":"Moran","year":"2010","journal-title":"Gynecol Obstet Invest"},{"key":"R26-7-20240905","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1477-7827-12-89","article-title":"The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: A community based study in Southwest of Iran","volume":"12","author":"Tehrani","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"R27-7-20240905","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.fertnstert.2008.06.013","article-title":"RETRACTED: Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: A prospective randomized trial","volume":"92","author":"Badawy","year":"2009","journal-title":"Fertil Steril"},{"key":"R28-7-20240905","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.fertnstert.2006.04.026","article-title":"Use of an aromatase inhibitor in patients with polycystic ovary syndrome: A prospective randomized trial","volume":"86","author":"Bayar","year":"2006","journal-title":"Fertil Steril"},{"key":"R29-7-20240905","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0974-1208.97789","article-title":"A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome","volume":"5","author":"Roy","year":"2012","journal-title":"J Hum Reprod Sci"},{"key":"R30-7-20240905","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/0974-1208.117166","article-title":"Current evidence supporting \u201cletrozole\u201d for ovulation induction (2003)","volume":"6","author":"Kar","year":"2013","journal-title":"J Hum Reprod Sci"},{"key":"R31-7-20240905","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2004-823028","article-title":"Aromatase inhibitors in ovulation induction","volume":"22","author":"Mitwally","year":"2004","journal-title":"Semin Reprod Med"},{"key":"R32-7-20240905","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.fertnstert.2012.10.008","article-title":"A historical perspective of aromatase inhibitors for ovulation induction","volume":"98","author":"Casper","year":"2012","journal-title":"Fertil Steril"}],"container-title":["Journal of Human Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.jhrs_141_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:04Z","timestamp":1787166664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.jhrs_141_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jhrs.jhrs_141_21","relation":{},"ISSN":["0974-1208"],"issn-type":[{"value":"0974-1208","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}